An international company based in Parma (Italy) with 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas. With a turnover of more than €1.3 billion sales Chiesi is among the top 50 pharmaceutical companies in the world. Production sites are in Parma, Italy, Blois (France) and Santana De Parnaiba (Brazil). They opened their Mexican affiliate in 2012.
Av. Coyoacán No. 1622
Edificio 2, Piso 1 Oficina 208
Col. Del Valle, Benito Juárez
C.P. 03100, México, D.F.
Asist. +52 (55) 4040-7200
Direct. +52 (55) 4040-7201
Mob. +52 1 (55) 4488-7202
e-mail. m.muniz@chiesi.com
website. www.chiesi.mx
Chiesi Mexico’s Marco Ruggiero discusses his initial impressions of the Mexican pharma market, his strategic priorities for the affiliate, and the increasing importance of the company’s respiratory portfolio in Mexico.…
Mario Muniz, general manager of Chiesi Mexico, explains how the affiliate looks at becoming a comprehensive solution provider in the neonatal field, highlights the dramatic consequences of the health budget…
Internationalization and innovation are part of Chiesi’s history. The general manager of the recently started Mexican affiliate discusses the company’s priorities for the second largest market in Latin America and…
The latest from Mexican pharma, including the distribution agreement between Dow and Azelis, Neuraxpharm’s new LatAm subsidiaries in Mexico and Brazil; Landsteiner Scientific’s restructure, and Merck’s plant expansion in Naucalpan.…
Latin America’s patient organisations are today playing a more important role than ever before in developing solutions to the continent’s most pressing healthcare challenges. Given the healthcare gaps that persist,…
Back in Latin America after several years in the US and Europe, Teva LatAm Head and Mexico GM Rodrigo Fernandez explains how the affiliate has adapted its strategy across the…
Mexico, with the second largest pharmaceutical market in Latin America, has a number of strong local pharma industry players. These companies, no longer focused solely on the domestic market, are…
María del Socorro España Lomelí, the executive director of Mexico’s National Association of Manufacturers of Medicines (ANAFAM), speaks to PharmaBoardroom about ANAFAM’s evolving relationship with the Mexican government and the…
Dagoberto Cortés Cervantes, president of Mexico’s National Association of Medicines Manufacturers (ANAFAM) and director of Grupo Sanfer/Hormona Mexico, outlines the expansion strategy that has led the manufacturing group to extend…
The Mexican Association of Pharmaceutical Research Industries (AMIIF) represents the innovative pharmaceutical industry in Mexico, advocating for innovation and promoting dialogue with local authorities. AMIIF’s Executive Director, Cristobal Thompson, discusses…
Latin America (LatAm) Area Lead for Astellas Sandra Ramirez outlines the Japanese company’s presence in the region, its efforts to partner with local stakeholders to improve patient access, and the…
Mexico’s pharma market, the second largest in Latin America and among the top 15 globally, is set to top USD 13 billion in sales by 2028. Despite the encouraging numbers,…
The director of Mexican pharmaceutical industry association CANIFARMA, Rafael Gual Cosío, speaks out about the current contradictions plaguing Mexico’s pharma sector. Gual Cosío highlights the fact that market growth and…
The latest from Latin American pharma, including Moderna’s push to build a regional presence and partnership network; Pfizer’s health equity challenges in the region; and Brazil’s local manufacturing of AstraZeneca’s…
The latest from Mexican pharma, including government talks with Indian authorities to provide low-cost medicines, a new distribution pilot program led by the military, the authorization of two Lilly monoclonal…
See our Cookie Privacy Policy Here